Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783510 · ClinicalTrials.gov registry record
Juvenile Idiopathic Arthritis (JIA) Registry
A clinical trial of Juvenile Idiopathic Arthritis and JIA, sponsored by AbbVie.
- Completed
- Registry status
- 849
- Enrollment target
- 20
- Study locations
NCT00783510: Completed study of Juvenile Idiopathic Arthritis and JIA, sponsored by AbbVie.
NCT00783510 is a study of Juvenile Idiopathic Arthritis and JIA that has completed, run by AbbVie. The registered enrollment target is 849 participants, above the 196-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (333% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783510, a study of Juvenile Idiopathic Arthritis and JIA, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 849 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be followed in both the Humira® and Methotrexate (MTX) arms for 10 years from the enrollment date into one of the treatment arms.
Primary Outcome
Collected as events occur during the registry and as part of prior clinical studies. Events are collected retrospectively for patients who dosed prior to enrollment in the registry and as part of the Health Care Provider (HCP) process.
Conditions Studied
Interventions
- DRUG Methotrexate
- BIOLOGICAL adalimumab
Study Locations (20)
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago /ID# 20966 - Chicago
- The University of Chicago Medical Center /ID# 21981 - Chicago
- Methodist Medical Group Rheum /ID# 46343 - Peoria
New York
- North Shore University Hospital /ID# 21022 - New Hyde Park
- University of Rochester Medical Center /ID# 20967 - Rochester
- New York Medical College /ID# 21964 - Valhalla
Arizona
- AZ Arthritis and Rheumotology Research, PLLC /ID# 21023 - Phoenix
- Catalina Pointe Clinical Research /ID# 40227 - Tucson
Arkansas
- Arkansas Children's Hospital /ID# 23505 - Little Rock
California
- Children's Hospital Los Angeles /ID# 24386 - Los Angeles
District of Columbia
- Children's National Medical Center /ID# 23506 - Washington D.C.
Florida
- Duplicate_Arthritis Associates South FL /ID# 17001 - Delray Beach
Indiana
- Indiana University /ID# 11421 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 849 participants |
| Start Date | 2008-07-11 |
| Est. Completion | 2024-02-01 |
What the finished NCT00783510 record still lists
NCT00783510 is an observational study that tracks outcomes without assigning an intervention. The registered 849 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (333% higher).
The record links to 2 conditions, with Juvenile Idiopathic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Methotrexate is the first listed.
NCT00783510 names 20 study sites across 15 states, led by Illinois, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT00783510 about?
NCT00783510 is a clinical study titled "Juvenile Idiopathic Arthritis (JIA) Registry". This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label. Patients treated with MTX will be considered a reference group. Patients will be...
What is the current status of trial NCT00783510?
This trial is currently completed. The enrollment target is 849 participants. The study started on 2008-07-11. Estimated completion is 2024-02-01.
What conditions does trial NCT00783510 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis, JIA.
What interventions are being tested in trial NCT00783510?
The interventions under investigation include: Methotrexate (DRUG), adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00783510?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00783510 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00783510's enrollment target sits among peer trials
849 1st of 8 higher than 8 of 8 other Juvenile Idiopathic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Juvenile Idiopathic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
RECRUITING · Phase 3
-
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
RECRUITING
-
Pain in Juvenile Arthritis
RECRUITING · NA
-
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
ACTIVE NOT RECRUITING
-
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
COMPLETED · Phase 2
-
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI